Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer

Clinical and Translational Oncology

Volumn 13, Issue 7, 2011, Pages 499-503

  Asher, Viren ^a   Lee, Joanne ^a   Innamaa, Anni ^a   Bali, Anish ^a  

^a ROYAL DERBY HOSPITAL   (United Kingdom)

Author keywords

Ovarian cancer; Platelet lymphocyte ratio; Prognostic marker

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; LAPAROTOMY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; OVARY CANCER; OVERALL SURVIVAL; PLATELET LYMPHOCYTE RATIO; PREOPERATIVE EVALUATION; RETROSPECTIVE STUDY; SURVIVAL TIME; THROMBOCYTE COUNT; ADENOCARCINOMA; BLOOD; COLLOID CARCINOMA; CYSTADENOCARCINOMA; ENDOMETRIUM TUMOR; LYMPHOCYTE; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PREOPERATIVE CARE; PROGNOSIS;

TUMOR MARKER;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LYMPHOCYTES; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PLATELET COUNT; PREOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 82255162065     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0687-9     Document Type: Article

References (30)

1. Cancer Research UK (2006) Ovarian cancer incidence statistics. Cancer Research UK. Available from: http://info.cancerresearchuk.org/cancerstats/types/ ovary/incidence/index.htm
2. Horner MJ, Ries LAG, Krapcho M et al (eds) (2009) SEER cancer statistics review, 1975-2006. Available from: http://seer.cancer.gov/csr/1975-2006/
3. Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249
4. Marchetti C, Pisano C, Facchini G et al (2009) First-line treatment of advanced ovarian cancer: current research and perspectives. Exp Rev Anticancer Ther 10:47-60
5. Ozols RF (2006) Challenges for chemotherapy in ovarian cancer. Ann Oncol 17[Suppl 5]:v181-187 (Pubitemid 43994856)
6. Gadducci A, Cosio S, Tana R, Genazzani AR (2009) Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol 69:12-27
7. Bast RC Jr, Badgwell D, Lu Z et al (2005) New tumor markers: CA125 and beyond. Int J Gynecol Cancer 15[Suppl 3]:274-281 (Pubitemid 43096594)
8. Gupta D, Lis CG (2009) Role of CA125 in predicting ovarian cancer survival: a review of the epidemiological literature. J Ovarian Res 2:13
9. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883-899
10. Hefler LA, Concin N, Hofstetter G et al (2008) Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res 14:710-714 (Pubitemid 351231151)
11. Li AJ, Madden AC, Cass I et al (2004) The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. Gynecol Oncol 92:211-214 (Pubitemid 38147393)
12. Bozkurt N, Yuce K, Basaran M et al (2004) Correlation of platelet count with second-look laparotomy results and disease progression in patients with advanced epithelial ovarian cancer. Obstet Gynecol 103:82-85 (Pubitemid 39248471)
13. Bishara S, Griffin M, Cargill A et al (2008) Pretreatment white blood cell subtypes as prognostic indicators in ovarian cancer. Eur J Obstet Gynecol Reprod Biol 138:71-75 (Pubitemid 351608106)
14. den Ouden M, Ubachs JM, Stoot JE, van Wersch JW (1997) Whole blood cell counts and leucocyte differentials in patients with benign or malignant ovarian tumours. Eur J Obstet Gynecol Reprod Biol 72:73-77 (Pubitemid 27091287)
15. Cho H, Hur HW, Kim SW et al (2009) Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 58:15-23
16. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539-545 (Pubitemid 32173595)
17. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436-444
18. Salazar-Onfray F, Lopez MN, Mendoza-Naranjo A (2007) Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev 18:171-182 (Pubitemid 46401435)
19. Chen LL, Ye F, Lü WG et al (2009) Evaluation of immune inhibitory cytokine profiles in epithelial ovarian carcinoma. J Obstet Gynaecol Res 35:212-218
20. Fumagalli LA, Vinke J, Hoff W et al (2003) Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J Immunother 26:394-402 (Pubitemid 37128551)
21. Fogar P, Sperti C, Basso D et al (2006) Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas 32:22-28 (Pubitemid 41803643)
22. Menczer J, Schejter E, Geva D et al (1998) Ovarian carcinoma associated thrombocytosis. Correlation with prognostic factors and with survival. Eur J Gynaecol Oncol 19:82-84 (Pubitemid 28040703)
23. Gungor T, Kanat-Pektas M, Sucak A, Mollamahmutoglu L (2009) The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors. Arch Gynecol Obstet 279:53-56
24. Zacharski LR, Memoli VA, Ornstein DL et al (1993) Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. J Natl Cancer Inst 85:1225-1230 (Pubitemid 23223528)
25. Bastida E, Ordinas A, Giardina SL, Jamieson GA (1982) Differentiation of platelet-aggregating effects of human tumor cell lines based on inhibition studies with apyrase, hirudin, and phospholipase. Cancer Res 42:4348-4352 (Pubitemid 13205923)
26. Holmes CE, Levis JE, Ornstein DL (2009) Activated platelets enhance ovarian cancer cell invasion in a cellular model of metastasis. Clin Exp Metastasis 26:653-661
27. Aliustaoglu M, Bilici A, Ustaalioglu BB et al (2010) The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment. Med Oncol 27:1060-1065
28. Ong SL, Garcea G, Thomasset SC et al (2008) Ten-year experience in the management of gallbladder cancer from a single hepatobiliary and pancreatic centre with review of the literature. HPB (Oxford) 10:446-458
29. Arrieta O, Michel Ortega RM, Villanueva-Rodríguez G et al (2010) Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxelcisplatin chemotherapy: a prospective study. BMC Cancer 10:50
30. Smith RA, Bosonnet L, Raraty M et al (2009) Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 197:466-472